Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
Overview
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Associated Conditions
- Hyperphosphataemia
Clinical Trials
FDA Approved Products
Sevelamer Carbonate For Oral Suspension
Manufacturer:Hangzhou Anprime Biopharm Co., Ltd.
Route:ORAL
Strength:2400 mg in 1 1
Approved: 2023/03/24
NDC:72823-302
Sevelamer hydrochloride
Manufacturer:Lupin Pharmaceuticals, Inc.
Route:ORAL
Strength:400 mg in 1 1
Approved: 2022/03/01
NDC:70748-172
Sevelamer Carbonate
Manufacturer:Cardinal Health 107, LLC
Route:ORAL
Strength:800 mg in 1 1
Approved: 2022/12/15
NDC:55154-8188
sevelamer hydrochloride
Manufacturer:Glenmark Pharmaceuticals Inc., USA
Route:PARENTERAL
Strength:800 mg in 1 1
Approved: 2020/06/30
NDC:68462-447
Sevelamer Carbonate
Manufacturer:NorthStar Rx LLC
Route:ORAL
Strength:800 mg in 1 1
Approved: 2023/12/08
NDC:16714-814
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath